Search Within

Marc Ladanyi

  1. "Molecular Cancer Therapeutics"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (2)
Groups
  1. Department of Pathology and Laboratory Medicine (7)
  2. GSK Faculty (7)
  3. Human Oncology and Pathogenesis Program (7)
  4. Tow Center for Developmental Oncology (TCDO) (7)
  5. Department of Medicine (6)
  6. Solid Tumor Oncology Division (6)

More Groups

People
  1. Gregory Riely (3)
  2. Mark Kris (3)
  3. Camelia Sima (2)
  4. Jamie Chaft (2)
  5. Lu Wang (2)
  6. Maria Arcila (2)

More People

Years
  1. 2024 (1)
  2. 2019 (1)
  3. 2015 (1)
  4. 2013 (1)
  5. 2012 (2)
  6. 2007 (1)
Publications
  1. Molecular Cancer Therapeutics (7)
Publishers
  1. American Association for Cancer Research (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFT bypass signaling
    Journal Article

    Chen, N.; Tyler, L. C.; Le, A. T.; Welsh, E. A.; Fang, B.; Elliott, A.; Davies, K. D.; Danhorn, T.; Riely, G. J.; Ladanyi, M.; more...
    Molecular Cancer Therapeutics (2024)

    Fulltext@MSK | Save
  • Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer
    Journal Article

    Meador, C. B.; Jin, H.; de Stanchina, E.; Nebhan, C. A.; Pirazzoli, V.; Wang, L.; Lu, P.; Vuong, H.; Hutchinson, K. E.; Jia, P.; more...
    Molecular Cancer Therapeutics (2015)

    Fulltext@MSK | Save
  • EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics
    Journal Article

    Arcila, M. E.; Nafa, K.; Chaft, J. E.; Rekhtman, N.; Lau, C.; Reva, B. A.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.
    Molecular Cancer Therapeutics (2013)

    Fulltext@MSK | Save
  • Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component
    Journal Article

    Paik, P. K.; Varghese, A. M.; Sima, C. S.; Moreira, A. L.; Ladanyi, M.; Kris, M. G.; Rekhtman, N.
    Molecular Cancer Therapeutics (2012)

    Fulltext@MSK | Save
  • Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
    Journal Article

    Chaft, J. E.; Arcila, M. E.; Paik, P. K.; Lau, C.; Riely, G. J.; Pietanza, M. C.; Zakowski, M. F.; Rusch, V.; Sima, C. S.; Ladanyi, M.; more...
    Molecular Cancer Therapeutics (2012)

    Fulltext@MSK | Save
  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    Meeting Abstract

    Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save